Advertisement

Medical device company Boston Scientific wins European regulatory approval to update the labels on its Promus Element and Promus Element Plus coronary stents to include 3-month DAPT therapy.

Boston Scientific logo

Medical device industry titan Boston Scientific (NYSE:BSX) won expanded CE Mark approval in the European Union to update the directions for use on its Promus Element and Promus Element Plus coronary stents.

The new labels can include 3-month dual anti-platelet drug therapy for certain patients, and Boston Scientific plans to introduce the new labeling in CE Mark countries, according to a press release.

Advertisement
Advertisement